Is losartan contraindicated in patients with heart failure?

Losartan is NOT Contraindicated in Heart Failure

Losartan is not contraindicated in heart failure; it is an accepted treatment option for patients with heart failure with reduced ejection fraction (HFrEF), particularly when ACE inhibitors are not tolerated. However, the commonly prescribed 50 mg daily dose appears inferior to ACE inhibitors for mortality reduction, and higher doses (150 mg daily) are needed to achieve optimal benefit 1.

Key Evidence from Guidelines and Drug Labeling

FDA-Approved Indications

The FDA label for losartan does not list heart failure as a contraindication 2. The actual contraindications are:

• Hypersensitivity to any component
• Coadministration with aliskiren in diabetic patients

Guideline Recommendations

ARBs (including losartan) are recommended in heart failure when:

• Patients are intolerant to ACE inhibitors 3, 4
• As an alternative in symptomatic patients (NYHA class II-IV) with LVEF ≤40% 5, 4

The 2022 AHA/ACC/HFSA guidelines explicitly state that ARBs should be used in patients with HFrEF who are ACE-inhibitor intolerant 6.

Critical Dosing Consideration

The major issue with losartan in heart failure is inadequate dosing, not contraindication:

• Standard 50 mg daily dose is INSUFFICIENT and appears inferior to ACE inhibitors for mortality reduction 1
• Target dose should be 150 mg daily - this is higher than approved for any cardiovascular indication in the US but is the evidence-based dose for heart failure 1
• The HEAAL trial demonstrated that 150 mg daily reduced death or heart failure hospitalization by 10% compared to 50 mg daily 7

Dosing Algorithm for Losartan in Heart Failure:

1. Starting dose: 12.5-25 mg daily 8
2. Uptitrate gradually every 2-4 weeks as tolerated
3. Target dose: 150 mg daily (not the commonly prescribed 50 mg) 1, 7
4. Monitor renal function and potassium at 1 and 4 weeks after each dose increase 4

When to Use Losartan vs. Other ARBs

Losartan is generally NOT the preferred ARB for heart failure. Other ARBs have stronger evidence:

• Candesartan (target 32 mg daily) and valsartan (target 160 mg twice daily) have more robust mortality data 1, 4
• A Danish registry study found no overall mortality difference between losartan and candesartan when comparing equivalent high doses, but low-dose losartan (50 mg) was associated with increased mortality 9

Safety Monitoring Requirements

Monitor closely but do NOT withhold treatment for:

• Mild hypotension (systolic BP <110 mmHg) - this should not prevent uptitration 6
• Mild worsening renal function (creatinine increase <100% or to <310 μmol/L) 5, 4
• Asymptomatic hyperkalemia <5.5 mmol/L 4

Consider dose reduction or temporary hold if:

• Potassium >5.5 mmol/L (reduce by 50%; stop if >6.0 mmol/L) 4
• Creatinine increases >100% or to >310 μmol/L (3.5 mg/dL) 5
• Symptomatic hypotension with end-organ hypoperfusion 2

Common Clinical Pitfalls

1. Using 50 mg daily as the "target dose" - this is inadequate and may explain inferior outcomes compared to ACE inhibitors 1
2. Stopping ARBs for mild BP drops or creatinine increases - these are expected pharmacologic effects and rarely require discontinuation 6
3. Choosing losartan over better-studied ARBs - candesartan and valsartan have stronger evidence in heart failure 4
4. Not uptitrating to target doses - most benefits occur at higher doses 1, 7

Bottom Line

Losartan is not contraindicated in heart failure but requires proper dosing (150 mg daily, not 50 mg) to match ACE inhibitor efficacy. When an ARB is needed for ACE-inhibitor intolerance, candesartan or valsartan are preferred over losartan due to stronger evidence 4. If losartan is used, aggressive uptitration to 150 mg daily is essential 7.